Research Interests:
My major research interest is in the diagnosis and treatment of systemic fungal
diseases. I am the Director of the San Antonio Center for Medical Mycology, a multi-disciplinary group of investigators with a diverse interest in medical mycology.  My laboratory is actively involved in developing new diagnostic methods for invasive aspergillosis.  I am the principal investigator for an NIH contract to develop standardized animal models of invasive aspergillosis in order to identify new diagnostic targets for aspergillosis and to develop new assays for early diagnosis of that often lethal infection.  My current research also includes detection and significance of antifungal
resistance in oropharyngeal candidiasis in patients with AIDS and other immunosuppressed hosts that is funded through the NIH/NIDCR.  This research is aimed at early detection of antifungal resistant yeasts and determining the significance of resistant yeasts in oropharyngeal infection.   My research also involves the evaluation of new antifungals both in animal models and in clinical studies.  We currently have active protocols for new therapeutic agents in Candida, Cryptococcus, Aspergillus and emerging fungal pathogens.

Unique Technical and Clinical Research Capabilities/Instrumentation:
Applied biosystems model 7300 Realtime PCR system, CHEF DRIII unit, Bio-Rad Molecular Analyst fingerprinting software, oral camera unit.

    • Patterson TF.  Advances and challenges in the management of invasive mycoses.  Lancet. 2005;366:1013-25

    • Patterson TF, Boucher HW, Herbrecht R, Denning DW, Lortholary O, Ribaud P, Rubin RH, Wingard JR, DePauw B, Schlamm HT, Troke P, Bennett JE; European Organization for Research and Treatment of Cancer (EORTC) Invasive Fungal Infections Group (IFIG); Pfizer Global Aspergillus Study Group.  Strategy of following voriconazole versus amphotericin B therapy with other licensed antifungal therapy for primary treatment of invasive aspergillosis: impact of other therapies on outcome Clin Infect Dis 2005;41:1448-52

    • Goldman M, Cloud GA, Wade KD, Reboli AC, Fichtenbaum CJ, Hafner R, Sobel JD, Powderly WG, Patterson TF, Wheat LJ, Stein DK, Dismukes WE, Filler SG. A randomized study of the use of fluconazole in continuous versus episodic therapy in patients with advanced HIV infection and a history of oropharyngeal candidiasis: AIDS Clinical Trials Group Study 323/Mycoses Study Group Study 40. Clin Infect Dis. 2005;41:1473-80

    • Lewis JS,II, Boucher HW, Lubowski T, Ambegaonkar A, Day D, Patterson TF. Cost advantage of voriconazole for the primary treatment of invasive aspergillosis. Pharmacotherapy 2005;25:839-46.

    • Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann J-W, Kern WV, Marr KA, Ribaud P, Lortholary O, Sylvester R, Rubin RH, Wingard JR, Stark P, Durand C, Caillot D, Thiel E, Chandrasekar PH, Hodges MR, Schlamm HT, Troke PF, DePauw B. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. New Engl J Med.

    • Kirkpatrick WR, Perea S, Coco BJ, Patterson TF. Efficacy of caspofungin alone and in combination with voriconazole in a guinea pig model of invasive aspergillosis. Antimicrob Agents Chemother 2002;46:2564-8.

    • Redding SW, Kirkpatrick WR, Coco BJ, Sadkowski L, Fothergill AW, Rinaldi MG, Eng TY, Patterson TFCandida glabrata oropharyngeal candidiasis in patients receiving radiation treatment for head and neck cancer.  J Clin Microbiol 2002;40:1879-81.

    • Perea S, López-Ribot JL, Wickes BL, Kirkpatrick WR, Dib OP, Bachmann SP, Keller SM, Martinez M, Patterson TF.  Molecular mechanisms of fluconazole resistance in Candida dubliniensis isolates from human immunodeficiency virus-infected patients with oropharyngeal candidiasis.  Antimicrob Agents Chemother 2002;46:1695-1703.

    • Perea S, López-Ribot JL, Kirkpatrick WR, McAtee RK, Santillán RA, Calabrese D, Martinez M, Sanglard D, Patterson TF. Prevalence of molecular mechanisms of resistance to azole antifungal agents in Candida albicans strains displaying high-level fluconazole resistance from Human Immunodeficiency Virus-infected patients. Antimicrob Agents Chemother 2001;45:2676-84.

    • Patterson TF, Kirkpatrick WR, White M, Hiemenz JW, Wingard JR, DuPont B, Rinaldi MG, Stevens DA, Graybill JR and the I3 Aspergillus Study Group.  Invasive aspergillosis:  Disease spectrum, treatment practices, and outcomes.  Medicine (Baltimore)  2000;79:250-60.

Health Science Center seal

Links provided from Health Science Center pages to other web sites do not constitute or imply an endorsement of those sites, their content, or products and services associated with those sites.
Best viewed at 1024x768 resolution.